Brachytherapy for cervix cancer: low-dose rate or high-dose rate brachytherapy – a meta-analysis of clinical trials by Viani, Gustavo A et al.
BioMed  Central
Page 1 of 12
(page number not for citation purposes)
Journal of Experimental & Clinical 
Cancer Research
Open Access Research
Brachytherapy for cervix cancer: low-dose rate or high-dose rate 
brachytherapy – a meta-analysis of clinical trials
Gustavo A Viani*1, Gustavo B Manta2, Eduardo J Stefano1 and Ligia I de 
Fendi3
Address: 1Radiation Oncology Department at Marilia School of Medicine, São Paulo, Brazil, 2Medical Student at Marília School of Medicine, São 
Paulo, Brazil and 3Department of Ophthalmology at Marília medicine school, São Paulo, Brazil
Email: Gustavo A Viani* - gusviani@gmail.com; Gustavo B Manta - gusviani@gmail.com; Eduardo J Stefano - stefano@famema.br; Ligia I de 
Fendi - lidefendi@yahoo.com.br
* Corresponding author    
Abstract
Background: The literature supporting high-dose rate brachytherapy (HDR) in the treatment of
cervical carcinoma derives primarily from retrospective series. However, controversy still persists
regarding the efficacy and safety of HDR brachytherapy compared to low-dose rate (LDR)
brachytherapy, in particular, due to inadequate tumor coverage for stage III patients. Whether LDR
or HDR brachytherapy produces better results for these patients in terms of survival rate, local
control rate and the treatment complications remain controversial.
Methods: A meta-analysis of RCT was performed comparing LDR to HDR brachytherapy for
cervix cancer treated for radiotherapy alone. The MEDLINE, EMBASE, CANCERLIT and Cochrane
Library databases, as well as abstracts published in the annual proceedings were systematically
searched. We assessed methodological quality for each outcome by grading the quality of evidence
using the Grading of Recommendations Assessment, Development and Evaluation (GRADE)
methodology. We used "recommend" for strong recommendations, and "suggest" for weak
recommendations.
Results: Pooled results from five randomized trials (2,065 patients) of HDR brachytherapy in
cervix cancer showed no significant increase of mortality (p = 0.52), local recurrence (p = 0.68), or
late complications (rectal; p = 0.7, bladder; p = 0.95 or small intestine; p = 0.06) rates as compared
to LDR brachytherapy. In the subgroup analysis no difference was observed for overall mortality
and local recurrence in patients with clinical stages I, II and III. The quality of evidence was low for
mortality and local recurrence in patients with clinical stage I, and moderate for other clinical
stages.
Conclusion: Our meta-analysis shows that there are no differences between HDR and LDR for
overall survival, local recurrence and late complications for clinical stages I, II and III. By means of
the GRADE system, we recommend the use of HDR for all clinical stages of cervix cancer.
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Introduction
Intracavitary radiation in the form of low-dose rate (LDR)
brachytherapy has been in use for the treatment of cervical
cancer for nearly a century, although the method has been
greatly refined. High-dose rate (HDR) brachytherapy for
carcinoma of the cervix has been in use for over 30 years.
LDR is defined as a dose of 0.4–2 Gray (Gy)/h, and HDR
is defined as a dose of >12 Gy/h [1]. HDR is widely used
throughout Asia and Europe, and its use is steadily
increasing in North and South Americas [2]. The Patterns
of Care Studies show that, in the United States, the use of
HDR for the treatment of cervical cancer increased from
9% during 1992–1994 to 16% during 1996–1999,
although this increase did not reach significance[3].
LDR techniques were developed in an era when remote
afterloading technology was unavailable, and remote
afterloading techniques were developed due to concerns
related to radiation exposure to health care workers. In
more recent years, new technology has allowed remote
afterloading brachytherapy to be given at LDR. The use of
HDR brachytherapy is the result of technological develop-
ment in the manufacture of high-intensity radioactive
sources, sophisticated computerized remote afterloading
devices, and treatment planning software [4]. Several
advantages of HDR brachytherapy, including rigid immo-
bilization, outpatient treatment, patient convenience,
accuracy of source and applicator positioning, individual-
ized treatment with source optimization, and complete
radiation protection for personnel have been claimed [5-
7].
There are nearly three decades of experience comparing
HDR to LDR brachytherapy in the treatment of cervical
carcinoma. The literature supporting HDR brachytherapy
in the treatment of cervical carcinoma derives primarily
from retrospective series [8-14]. However, controversy
still persists regarding the efficacy and safety of HDR
brachytherapy compared to low-dose rate (LDR) brachy-
therapy [2-4,15]. In particular, due to inadequate tumor
coverage for stage III patients, whether LDR or HDR
brachytherapy produces better results for this patients in
terms of survival rate, local control rate and treatment
complications remain controversial.
So, the goal of this study was to conduct a meta-analysis
to compare the efficacy and safety of HDR and LDR brach-
ytherapy in patients with cervix cancer. In addition to that,
we found it appropriate to build the recommendations for
the use of HDR based on the GRADE system.
Materials and methods
Criteria for considering studies for this review included
the following:
Studies
RCTs or overviews of RCTs comparing LDR brachytherapy
to HDR brachytherapy in patients with cervical carcinoma
treated with radiotherapy alone or combined to chemo-
therapy, which were fully published in journals and those
identified from other sources (abstracts and proceedings
of relevant scientific meetings, and contact with investiga-
tors).
Study population
Patients with histologically confirmed cervical cancer and
at least 18 years of age.
Interventions
Trials that compared HDR brachytherapy to LDR brachy-
therapy following pelvic radiotherapy.
Outcome measures
Overall mortality, local recurrence and treatment compli-
cations. The databases MEDLINE (Ovid) (1996–May,
2007), CANCERLIT (Ovid) (1996–March 2007) and the
Cochrane Library (Issue 2, 2007) were searched for trials
using the terms: 'low-dose rate' (Medical Subject Heading
[MeSH]), 'high-dose rate' (text words), 'intracavitary radi-
otherapy' (text word), 'brachytherapy' (text word) and
'cervical cancer' or 'cervix cancer' (MeSH and text word).
These terms were then combined with the search terms for
the following study designs: practice guidelines, system-
atic reviews or meta-analyses, reviews, randomized con-
trolled trials and controlled clinical trials. In addition, the
Physician Data Query (PDQ) clinical trials database on
the Internet http://cnetdb.nci.nih.gov/trialsrch.shtml, and
the proceedings of the 1997–2007 annual meetings of the
American Society of Clinical Oncology (ASCO) and the
American Society of Radiation Therapist (ASTRO) were
searched for reports of new or on-going trials. Relevant
articles and abstracts were selected and reviewed by two
methodologists, and the reference lists from these sources
were searched for additional trials. Randomized trials
identified by the search were assessed to determine
whether they met the inclusion criteria. They were
assessed by two independent reviewers (V GA., S EJ.). Dis-
crepancies were resolved by a third reviewer (F LI.).
Analysis of the review
We used two techniques to calculate the pooled odds ratio
(OR) estimates: the Mantel-Haenszel method [16] assum-
ing a fixed-effects model and the Der Simonian-Laird
method [17] assuming a random-effects model. The fixed-
effects model leads to valid inferences about the specific
studies that have been assembled, and the random-effects
model assumes that the particular study samples were
drawn from a larger universe of possible studies and leads
to inferences about all studies in the hypothetical popula-
tion of studies. The random-effects approach often leadsJournal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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to wider confidential intervals (CIs). In the absence of het-
erogeneity, the fixed and random-effects models provide
similar results. ORs less than unity indicated a treatment
effect that favored the study agent. Pooled, weighted ORs
and their respective 95% CIs were then estimated sepa-
rately per each outcome for each meta-analysis.
In the RCTs that have reported the severity of complica-
tions classified according to the Radiation Therapy Oncol-
ogy Group (RTOG) or other score systems were combined
when possible. Subgroup analyses for each outcome were
performed by recalculating the ORs and 95% CIs, based
on the clinical stage of the disease. We evaluated heteroge-
neity across trials using the I2 statistics, which describes
the percentage of total variation across studies that are due
to heterogeneity rather than chance [18]. The interpreta-
tion of I2 depends on the magnitude and direction of
effects, as well as the strength of evidence for heterogene-
ity (e.g. P value from the chi-squared test, or a confidence
interval for I2) [19]. We used the following classification
based on the value of I2 [17,18]: 0–30 = low; 30–60 =
moderate and worthy of investigation; 60–90 = severe and
worthy of understanding; 90–100 = allowing aggregation
only with major caution. Publication bias is a common
concern in meta-analysis, which is related to the tendency
of journals to favor the publication of large and positive
studies. Quality of the evidence has been assessed using
the grade four-category system (high, moderate, low and
very low quality) (Table 1). Factors that are considered in
classifying evidence are: the study design and rigor of its
execution, the consistency of results and how well the evi-
dence can be directly applied to patients, interventions,
outcomes and comparator. Other important factors are
whether the data are sparse or imprecise and whether
there is potential for reporting bias. Using this approach,
assessments of the quality of evidence for each important
outcome take into account the study design, limitations of
the studies, consistency of the evidence across studies, the
directness of the evidence, and the precision of the esti-
mate [20,21].
For each intervention considered, we formulated a con-
sensus recommendation based on our judgments, regard-
ing the balance between the benefits, harms (adverse
effects), costs, and values and preferences of the interven-
tion. Then, recommendations have been classified as
"strong" or "weak." (Table 2)
We chose a commonly used method for detecting publi-
cation bias, which is a graphical plot of estimates of the
odds ratios from the individual studies versus the inverse
of their variances, which is commonly referred to as a
"funnel plot." The analyses were performed using com-
prehensive meta-analysis software (Revman 5.0).
Results
The two trial assessors agreed on the selection of five
RCTs. The Quorum flow diagram illustrates the main rea-
sons for trial exclusion (Figure 1). The overall sample
included 2,145 patients in 5 RCTs comparing LDR to
HDR [22-26]. The published studies are described in
Table 3 and the quality of studies is described in Figure 2
and Figure 3
Methodological quality of included studies
Following the GRADE system, the study design for all tri-
als included in the review of evidence for HDR and LDR
was randomized controlled trial, which is scored as a high
type of evidence. As requested from the methodology of
GRADE, study quality was also assessed by reviewing
whether the studies had limitations or flaws. The follow-
ing limitations were noted, leading frequently to a
decrease in the quality of evidence: methods of randomi-
zation were not clearly reported, allocation concealment
was not reported or unclear, none of trials were blinded,
incomplete descriptions of withdrawals and dropouts
were reported, analyses were based on the per protocol or
completer population and not on the intention-to-treat
population and none of studies reported a priori sample
size calculations. The percentage follow-up ranged from
89% to 100%. None of the studies was interrupted early
for benefit. The methodological quality varied by out-
Table 1: Quality of the quality evidence, definitions and underlying methodology
Grade Definition Underlying Methodology
High Further research is very unlikely to change our confidence in the estimate of 
effect
RCT or meta-analysis
Moderate Further research is likely to have an important impact on our confidence in the 
estimate of effect and may change the estimate
Downgraded RCTs or upgraded observational studies
Low have an important impact on our confidence in the estimate of effect an its 
likely to change the estimate
Well-done observational studies with control groups
Very low Any estimate of effect is very uncertain Others (e.g., case reports or case series)Journal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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come. It was low for mortality and local recurrence in clin-
ical stage I and moderate for other outcomes (Figure 2,
Figure 3). Figure 2 and Figure 3 also provide the absolute
reductions in the risks of different outcomes for a number
of illustrative baseline risks, including medium baseline
risks.
Overall mortality
Five studies reported overall mortality as one of the out-
comes. Altogether, the analyses included 5 trials with
2,065 patients. The overall mortality rates were not
decreased for LDR arm (340/997 = 34.1%) compared to
HDR arms (375/1068 = 35.1%). The overall odds ratio
(OR = 0.94, CI 95% -0.78, 1.13) suggests that there is no
difference between LDR arms and HDR arms in terms of
overall mortality rate with p value 0.52, as demonstrated
in Figure 4. The test for heterogeneity was not statistically
significant with p value 0.98, which indicates that the
pooling of the data was valid. In the subgroup analysis
there was no difference for overall survival among differ-
ent clinical stages I, II and III, as demonstrated in Table 4.
Local recurrence
Five trials reported on local control. There was no signifi-
cant difference for local recurrence among those patients
receiving LDR brachytherapy and HDR brachytherapy
(OR = 1.05(CI 95% 0.85–1.29), as Figure 5. The test for
heterogeneity was not statistically significant with p value
068, which indicates that the pooling of the data was
valid. In the subgroup analysis there was no difference for
overall survival among different clinical stages I, II and III,
as demonstrated in Table 4.
Grade 3 or 4 Rectal, Bladder or Small Intestine 
complications
Five trials evaluated rectal or bladder complications. For
grade 3 or 4 rectal and bladder complication, there was no
significant difference between HDR and LDR, as demon-
strated in Table 4. Only 3 studies reported the small intes-
tinal complications as one of its outcomes. No significant
difference was observed between the treatment arms, con-
sidering grade 3 or 4 complication, as showed in Table 4.
Discussion
Approximately 11,070 women are diagnosed with cervical
cancer annually in the US, resulting in 3,870 deaths [27].
This represents 0.13 percent of all cancer deaths in
women. Despite this, and the promise of newly developed
cervical carcinoma vaccines [28], cervical carcinoma is still
the third largest cancer killer of women world-wide, caus-
ing 274,000 deaths in 2002 [29]. Cervix cancer is a curable
cancer, but achieving the best results depends on well-
organized and appropriately resourced cancer services.
Brachytherapy is an integral part of the cervical carcinoma
treatment armamentarium. It is a technically demanding
and highly specialized method of radiotherapy delivery.
Depending on the equipment used, the capital expendi-
tures and staff costs may be high. Fractionated HDR
brachytherapy in the treatment of uterine cervix cancer
has been increasing worldwide, including in the United
States [2]. In developing countries such as Brazil, the
advantages of outpatient treatment, potential cost savings,
radiation protection, patient comfort, reduction of the
need for general anesthesia, and less chance of applicators
displacement make of this procedure an excellent treat-
ment option [30]. Unfortunately, a well-designed pro-
spective and randomized Phase-III trial with an adequate
number of patients that would allow comparison of
results between LDR and HDR brachytherapy in the treat-
ment of cervix cancer has not yet been published. Thus,
we have performed a meta-analysis to improve the statics
precision of the outcomes in the clinical trials that com-
pared these two techniques. Meta-analysis of randomized
trials allows a more objective appraisal of the evidence,
which may lead to the resolution of uncertainty and disa-
greement. It works as a valuable tool for studying rare and
unintended effects of a treatment, by permitting synthesis
of data and providing more stable estimates of effect.
Table 2: Strength of recommendations and implication to quality of evidence.
Recommendation or statement Description in GRADE approach Interpretation
Strong recommendation We recommend (should) 1. Most individuals should receive the intervention, assuming that 
they have been informed about and have understood its benefits, 
harms and burden.
2. The recommendation could unequivocally be used for policy 
making.
Weak recommendation We suggest (might) 1. Uncertainty about the relative importance of the benefits and 
downsides to those affected, or differences in how important they 
are to different people, which could affect the balance between the 
benefits versus harms and burden
2. Doubt about the recommendation could be use for policy makingJournal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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Flowchart according to QUOROM statement criteria, informing the reason of some trials to be excluded Figure 1
Flowchart according to QUOROM statement criteria, informing the reason of some trials to be excluded.Journal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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Summary of findings (SoF) table using GRADE methodology for overall mortality Figure 2
Summary of findings (SoF) table using GRADE methodology for overall mortality.
Summary of findings (SoF) table using GRADE methodology for local recurrence Figure 3
Summary of findings (SoF) table using GRADE methodology for local recurrence.Journal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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Our results analyzing five RCTs (2,065 patients) really
confirm the use of HDR as an alternative to LDR for all
stages of cervical carcinoma. The overall survival and local
control were similar in both groups for stages I, II and III
(Figure 2 and Figure 3).
However, considering the clinical stage III a wide range of
results has been found in the literature [31-36]. Vahrson
and Romer [14] reported a significantly greater survival
rate for stage-III patients using HDR brachytherapy. In the
series of Ferrigno et al [37] stage-III patients treated with
HDR brachytherapy had a poorer outcome when com-
Table 3: Characteristics of clinical trials
Year Study Patients Fraction of LDR
(Gy/fraction)
Fraction of HDR
(Gy/Fraction)
Pelvic RT Dose
(Gy)
Clinical stage
LDR HDR
2004 Lertsanguansinchai 237 25–35/2 15–16.6/2 40–50 IB-5 IB-7
IIA-2 IIA-1
IIB-61 IIB-64
IIIB-41 IIIB-40
2002 Hareyama 132 IIA-50/4 IIA-29,5/4 30–40 II-26 II-22
IIB-40/3 IIB-23,3/3 or 4 III-39 III-45
III-30/3 III-17,3/3 or 2
1993 Teshima 430 I-56/2 I-28/4 16–20 I-28 I-32
II-57/2 II-30/4 II-61 II-80
III-58/2 III-29/3 III-82 III-147
1994 Patel 482 I-II>3 cm-75/2 I-II>3 cm-38/2 35–40 I-39 I-35
I-II<3 cm-35/1 I-II<3 cm-18/2 II-93 II-90
III-35/1 III-18/2 III-114 III-111
2006 Shrivastava 800 I and II-60/2 I and II-35/5 40/20 I II-200 I II-200
III-30/1 III-21/3 III-200 III-200
Overal mortality for all clinical stages in cervix cancer Figure 4
Overal mortality for all clinical stages in cervix cancer.Journal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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pared with those treated with LDR brachytherapy. Overall
survival and disease-free survival at a 5-year period was
statistically superior in the LDR group. These results prob-
ably are caused by the different tumor-related prognostic
factors in stage-III patients, including tumor volume,
extension of parametrial invasion (unilateral or bilateral),
presence of hydronephrosis, lymph node metastasis, and
extension of vaginal involvement. Consequently, when
these patients do not receive radiotherapy combined to
chemotherapy, they may still have a large volume of dis-
ease at the time of brachytherapy, even if one waits until
the end of 5 weeks of daily treatment. With a large tumor
volume at brachytherapy, point-A prescription simply
does not cover the tumor volume. The current treatment
plan and technique for gynecological brachytherapy is
still based on the conventional, orthogonal film-based
approach developed 40 years ago. The source loading and
dose prescription of a conventional point-A plan in cervi-
cal cancer is not consistent with the individual tumor
extent, resulting in either undercoverage of the tumor
extent or unnecessary dosage of the surrounding normal
tissue. So, in order to safely treat large volume disease (i.e.
stage-IIIB patients), three dimensional (3D) image-based
treatment planning is necessary to ensure proper tumor
coverage. Several investigators have studied three dimen-
sional (3D) image-based brachytherapy planning using
Table 4: LDR versus HDR for overall mortality, local recurrence and late complications
Overall mortality
Stage Number of studies Total patients Patients/events
HDR
Patients/events
LDR
OR CI95% P value
I 2 134 19/67 13/67 0.68 0.36–1.29 0.23
II 4 500 75/257 62/243 0.84 0.56–1.24 0.38
III 5 1079 238/572 228/507 1.22 0.95–1.56 0.11
Local recurrence
Stage Number of studies Total patients Patients/events
HDR
Patients/events
LDR
OR CI95% P value
I 2 134 7/67 3/67 2.31 0.61–8.71 0.22
II 4 500 45/257 34/243 1.17 0.74–1.85 0.51
III 5 1079 143/572 138/507 0.94 0.70–1.27 0.70
Grade 3 or 4 rectal complication
Number of studies Total patients Patients/events
HDR
Patients/events
LDR
OR CI95% P value
5 2065 27/1068 27/997 0.9 0.52–1.56 0.7
Grade 3 or 4 bladder complication
Number of studies Total patients Patients/events
HDR
Patients/events
LDR
OR CI95% P value
5 2065 17/1068 16/997 0.98 0.49–1.96 0.95
Grade 3 or 4 small intestine complication
Number of studies Total patients Patients/events
HDR
Patients/events
LDR
OR CI95% P value
3 783 13/432 3/351 3.15 0.9–10.37 0.06Journal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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ultrasonography, computed tomography (CT), magnetic
resonance imaging (MRI), and positron-emission tomog-
raphy (PET) in cervical cancer [38-46]. Although the stud-
ies had some different findings, the conventional point-A
plan, compared with the 3D image-guided plan, generally
overestimated the minimal dose delivered to the target
volume and underestimated the maximal doses to the rec-
tum and bladder [40,42-46]. In addition to that, 3D
image-guided planning allows the evaluation of individ-
ual dose distributions applied to a certain volume, such as
the gross tumor volume (GTV), clinical target volume
(CTV), and organs at risk. Recently, the GEC-ESTRO work-
ing group for gynecologic brachytherapy introduced
guidelines for contouring the target volumes and organs
at risk (OARs) for 3D image-based treatment planning in
cervical cancer [41]. It is therefore imperative with HDR
for large volume disease that the practitioners contour the
normal tissues and look at the dose volume values to try
to minimize normal tissue dose.
Despite these limitations for large tumors (i.e. stage-IIIb
and tumors > 4 cm), in recent years, HDR brachytherapy
has gained popularity due to the obvious physical advan-
tages of shortened treatment time and better geometric
placement. A second major reason for conversion from
LDR to HDR is reduced hospitalization. For each LDR
patient of around one week of hospitalization is required,
whereas, with HDR, this can be reduced to a maximum of
one day. In many countries, hospitalization of patients is
very expensive and methods to reduce this cost are
encouraged. In others, the availability of hospital beds is
a problem, especially beds in rooms suitably placed or
shielded for LDR brachytherapy. There is also the problem
of morbidity due to the long periods of bed-rest associated
with LDR treatments. One concern with LDR intracavitary
brachytherapy is the stability of positioning of the appli-
cators during the long periods of treatment. Dose calcula-
tions are performed soon after the applicators are inserted
and before they are loaded. On the few occasions that a
second dosimetric study has been performed on treat-
ment completion, this assumption has been shown to be
erroneous. For example, a recent study of data from five
institutions where dose distributions have been deter-
mined both at the beginning and at the end of an intrac-
avitary application with LDR has demonstrated that 'hot-
spot' dose rates to bladder and rectum increased during
treatment at an average rate of 7% and 19% respectively,
with negligible change in the dose rate to Point A [47].
Our results comparing late rectal and bladder complica-
tions in patients treated by HDR brachytherapy to LDR
brachytherapy show that there is no difference between
these two techniques. Similar probability of late compli-
cations in rectal, bladder or small intestine was observed
in both groups (Table 4).
Theoretically, HDR involves a greater probability of late
effects for a given level of tumor control; however, the
Local recurrence for all clinical stages in cervix cancer Figure 5
Local recurrence for all clinical stages in cervix cancer.Journal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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fractionation of HDR intracavitary brachytherapy appears
to offset this difference in tumor and normal tissue effects
caused by an increase in dose rate.
Despite its radiobiological disadvantages mentioned by
Eifel [48], the possibility of optimizing dose distribution
and the lesser chance of applicator displacement seem to
outweigh these disadvantages. Furthermore, the variation
of dwell time with the single stepping source permits an
almost infinite variation on the effective source strength
and source positions, which allows for greater control of
dose distribution and potentially less morbidity [25].
None of the RCTs in the literature show a higher incidence
of late complications in patients with cervix cancer treated
with HDR brachytherapy compared to those treated with
LDR. In our meta-analysis, incidence of lower 5-year rectal
complication in patients from the HDR group was proba-
bly the result of the relatively low dose delivered to the
rectum with the HDR brachytherapy fractionation used.
In LDR brachytherapy, the total rectal dose was com-
monly limited to 70 Gy. In HDR brachytherapy, this total
dose was lower, depending on the fractionation used;
however, how much lower remains unclear. Using the lin-
ear quadratic formula (total BED = BED EBR + BED HDR
= nd [1+(d /3)] +Br [1+(Br/3)], where n = number of EBR
fractions, d = dose of EBR fraction in Gy, and Br = total
dose of HDR brachytherapy at Point A), the total dose to
the rectum of 70 Gy with LDR brachytherapy corresponds
to 120 Gy3 with HDR brachytherapy.
But, what is the optimal HDR fractionation schedule for
treating cervical cancer? There is not a simple answer for
this question. Although universally efficacious, HDR frac-
tionation schedules cannot be ascertained, certain deduc-
tions can be made about the literature: No clear consensus
of the appropriate number of fractions or the dose per
fraction has been reached. Various fractionation schemes
have been used "experimentally" in search of the "opti-
mal" technique.
The GRADE system is based on a sequential assessment of
the quality of evidence, followed by an assessment of the
balance between benefits versus downsides, as well as the
subsequent judgment about the strength of recommenda-
tions. Because frontline consumers of recommendations
will be most interested in the best course of action, the
GRADE system places the strength of the recommenda-
tion first, followed by the quality of the evidence. Separat-
ing the judgments regarding the quality of evidence from
judgments about the strength of recommendations is a
critical and specific feature of this new grading system. In
our meta-analysis, the quality of evidence was moderate
for mortality and local recurrence for all clinical stages,
except for clinical stage I. Moreover, all included studies
were RCTs with moderate percentages of follow-up. This
moderate quality of evidence for mortality and local
recurrence, and the low likelihood of publication bias,
increase the confidence in the internal validity of our find-
ings. Thus, our data are different of a previous and more
extensive multi-institutional study including 17,068
patients treated with HDR and 5,666 with LDR at 56 insti-
tutions published by Orton et al. [49]. This involved a
combination of both published data and information,
collected via a questionnaire. A meta-analysis was per-
formed on the combined data sets. The overall 5-year sur-
vival rates were similar, being 60.8% for HDR and 59.0%
for LDR although, because of the large number of
patients, the difference bordered on statistical significance
(p < 0.045). However, since no randomization was
involved, the use of p-values to demonstrate statistical sig-
nificance in this context is questionable, especially with
such comparable survival rates. For Stage-III patients,
however, the difference in five-year survival rates was
somewhat more significant, being 47.2% for HDR com-
pared to 42.6% for LDR (p < 0.005).
The comparative results observed in our meta-analysis
must be interpreted with caution, since the data compar-
ing HDR to LDR for cancer of the cervix are fraught with
bias and may be difficult to compare, due to both a lack
of detailed information on the radiation administered
and a wide range of external beam and intracavitary dose
and fractionation schedules. Moreover, all of 5 selected
studies labeled "randomized" are, in fact, not truly rand-
omized studies and all have substantial flaws in their
methodology for 'randomization'. Thus, although we
have used the GRADE approach to rate the quality of evi-
dence and strength of recommendation, the need for
judgment is still required. Indeed, RCTs or meta-analysis
could have important methodological differences that
may impact on the results.
Conclusion
High-dose rate brachytherapy showed comparable clini-
cal results to LDR brachytherapy. In the subgroup analysis
there is no significant difference between HDR or LDR
brachytherapy considering the loco-regional recurrence,
overall mortality and treatment related to late toxicities
for patients with clinical stages I, II and III. Using the
GRADE system, we recommend the use of HDR for all
clinical stages of cervix cancer. Due to some potential dis-
advantages of LDR brachytherapy, such as radiation expo-
sure of the professional staff, the need for hospitalization,
the risk of anesthesia, bed immobilization that can lead to
thromboembolism, discomfort of vaginal packing and
applicators during bed immobilization, and displacement
of the applicators, HDR brachytherapy should be consid-
ered a standard treatment strategy for patients with cervi-
cal cancer, especially in developing countries, where this
procedure would have greater advantages than LDRJournal of Experimental & Clinical Cancer Research 2009, 28:47 http://www.jeccr.com/content/28/1/47
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brachytherapy. However, although a large number of frac-
tionation schedules are in use for HDR brachytherapy, the
optimal schedule has yet to be decided. Further trials are
necessaries to investigate 3D brachytherapy, fractionation
and dose adjustments of the total dose to reduce the fre-
quency of complications without compromising the treat-
ment results.
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